机构:[1]Qujing First Peoples Hosp, Dept Neurol, Qujing 650000, Yunnan, Peoples R China[2]Qujing First Peoples Hosp, Dept Pediat Med, Qujing 650000, Yunnan, Peoples R China
Objectives. Epilepsy is a chronic neurological disorder that is characterized by episodes of seizure. Methods. In this study, patients with status epilepticus in the Intensive Care Unit of the Department of Neurology of Qujing First People's Hospital were collected and treated with levetiracetam injection, continuous bedside EEG monitoring (cEEG) technology, and quantitative EEG (qEEG) technique. The inhibitory effects of different doses of levetiracetam injection and sodium valproate on abnormal discharge, the improvement of clinical symptoms, the incidence of adverse reactions, and prognosis were monitored, analyzed, and compared. Results. Compared with the experimental group of sodium valproate, 1000 mg/d levetiracetam group and 1500 mg/d levetiracetam group had a high probability of successful symptom control and a short control time. The patients had a low recurrence rate and a long recurrence time, and the probability of abnormal discharge in EEG was low. Conclusions. The recording results showed that levetiracetam could significantly inhibit the abnormal discharge of patients. Compared with sodium valproate, high-dose levetiracetam is a drug with a rapid effect, good effect, and long action time.
基金:
+is work was supported by Evaluation and prognostic
analysis of levetiracetam injection in the treatment of refractory
epileptic persistent state (2019017).
第一作者机构:[1]Qujing First Peoples Hosp, Dept Neurol, Qujing 650000, Yunnan, Peoples R China
通讯作者:
推荐引用方式(GB/T 7714):
Wu Haohao,Liu Jia,Qian Fang,et al.Clinical Evaluation of Levetiracetam in the Treatment of Epilepsy[J].JOURNAL OF HEALTHCARE ENGINEERING.2022,2022:doi:10.1155/2022/3789516.
APA:
Wu, Haohao,Liu, Jia,Qian, Fang,Yang, Junsu,Wang, Yue&Guan, Shaoyong.(2022).Clinical Evaluation of Levetiracetam in the Treatment of Epilepsy.JOURNAL OF HEALTHCARE ENGINEERING,2022,
MLA:
Wu, Haohao,et al."Clinical Evaluation of Levetiracetam in the Treatment of Epilepsy".JOURNAL OF HEALTHCARE ENGINEERING 2022.(2022)